(NASDAQ: ELTX) Elicio Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.5%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 76.11%.
Elicio Therapeutics's earnings in 2026 is -$39,571,000.On average, 4 Wall Street analysts forecast ELTX's earnings for 2026 to be -$28,239,813, with the lowest ELTX earnings forecast at -$31,008,422, and the highest ELTX earnings forecast at -$24,917,482. On average, 3 Wall Street analysts forecast ELTX's earnings for 2027 to be -$26,269,594, with the lowest ELTX earnings forecast at -$25,239,414, and the highest ELTX earnings forecast at -$27,042,229.
In 2028, ELTX is forecast to generate -$27,207,793 in earnings, with the lowest earnings forecast at -$26,140,821 and the highest earnings forecast at -$28,008,023.